And our third annual Healthcare Innovation Conference. My name is Yatin Suneja, one of the senior biotech analysts here at the firm. It is my pleasure to welcome our next presenting company, Latigo Biotherapeutics. From the company, we have the chief, or newly minted Chief Executive Officer, Todd Smith. Todd, I've prepared a Q&A for you, but why don't you make some opening comments? You just joined the company, I would say last week, or just a few days ago. How was the transition? Why you joined at this juncture? And just maybe introduce the Latigo story to our audience.
Yeah. Well, first of all, thank you, and good morning, everybody. As Yatin mentioned, I'm brand new. This is my day four as the CEO of Latigo. Excited to join it, right? I think one of the things Latigo's trying to do, we're trying to build ourselves into the innovative pain company. And I'd been on the board since early summer and got to see the pretty amazing team. I got to see the progression of the clinical data, both for LTG-321 and for onzotrigine. And so, for me, very excited to join the team and continue to help them build out what they've started. They had a very successful IPO. And so, my background, which might help understand why I'm stepping in at this time, is really centered around commercial, building out companies, launching products, and commercializing in this space.
I have over 15 products that I've been able to launch or manage in the pain space. Recently, I just sold a company called Corium to Collegium. Wrapped that up at the end of summer. It was a company that was underperforming commercially and operationally. We were able to turn it around in about 20 months, and then had an exit for the investors that returned fully back to the investors at that time. So, that made me available at the end of summer, and as we worked with the board, determined that as the next phase for Latigo is in this commercial build-out, commercial preparation for onzotrigine launch, seemed like the right time to make that change. I had some other opportunities. I made the decision to step in.
I think with that, my background then further goes into, which I think is important for everybody to understand, was at Horizon Pharma as the first Chief Commercial Officer. Got the first product approved. We IPO'd, and then we launched, and launched subsequently about five pain and NRA products at that time, and obviously had success there. So, I'm excited to be joining at this time. I think we have a lot of excitement as we look at next year. Second half of next year, we should have two readouts for both the OA trial for LTG-321, and we should have it for the bunionectomy trial for onzotrigine. We are also excited about the deeper pipeline as we look at LTG-418, which is a novel product unto itself with potentially more potency and the ability to continue to be once a day as well.
And then we have further work being done to look at other assets and targets as we continue to build out Latigo.
Got it. Very good. Todd Smith, thank you for that intro. Maybe just stepping back at a high level, pain has always been a very difficult area, right? I think it was only until after Vertex came up with their molecule we started seeing more development happening. If you look at the space, what do you think why we are seeing sort of this development or interest in the pain space?
Yeah. No, it's a great question because one of the things, as someone who's been in pain for, gosh, over 30 years, launched one of the first really novel pain drugs after the opioids, launching ketorolac back in the early 1990s, realizing how innovative that was, and then seeing some of the innovation in pain drugs through the late 1990s, early 2000s. Then there was really nothing at that point, right? What was kind of characteristic was this focus on the opioid crisis. I think there wasn't a whole lot of new things coming out, so I think on top of that, I think people just kind of settled in. We had NSAIDs, we had opioids. You have kind of two sides of this picture.
Opioids obviously have the societal risk and the human risk of overdose, but they also have clinically suboptimal when you think about great pain management, but clinical experience is very difficult, right? You have dizziness, you have OIC, you have inability to kind of release patients because of all these issues, and it's difficult. On the other side, you have the NSAIDs, which again have their own success and properties, whether it's anti-inflammatory and anti-pain, but they have significant side effects as well. At some point, pain's such a critical part. We have over 80 million people in the U.S. that have pain related around OA or acute pain. So there is a need for something new when you have that big of a need. I think people have always said pain's the largest unmet need market out there, right?
Then you start to see the validation of the NaV targets, the NaV1.8 particularly as lead. I think Vertex obviously launched about two years ago now, the NaV1.8, and they validated the asset, the class. I think we see it, right? They have over two million scripts on a run rate basis and growing. They grew 50% quarter-over-quarter in script volume. Yet, as novel and as important as suzetrigine is from Vertex, we know that it doesn't have quite the efficacy that I think most pain doctors would say, "Hey, that's a game changer for them." We saw that they also have drug-drug interactions. Again, a good product validating the class, but then we see obviously a lot of other groups, ourselves included, leading with NaV1.8. We see obviously other companies starting to build it out.
There is definitely a need, and I think we're also looking at multimodal with 1.7s, 1.9s, the Kvs. So there's a great resurgence now in innovation, development, and then ultimately what comes with that is you'll see then further work being done around investigator-initiated studies. You'll see work being done on testing other. That's great for the space because there's clearly a need for better treatments. There's clearly a need economically for better outcomes, and ultimately physicians are always seeking the best way to treat patients, and when that doesn't exist, we'll see them move towards that. Now what we need to do is continue to work on the market around either policy and then ultimately payers.
Got it. Very good. Thank you for that. Let's just focus on the molecules that you have. So onzotrigine, could you talk about how that product is designed to differentiate from JOURNAVX, and maybe touch a little bit on the data that you have already generated in abdominoplasty?
Yeah. This is one of the reasons I got very excited is I think when, as people know, onzotrigine data, initial abdominoplasty data got published in The New England Journal of Medicine in the summer. When you see that data, you get very excited, right? I think the SPID48 scores of 62, they showed about a 50% better response than Vicodin and about a 30% better response than suzetrigine when you look at cross-trial comparison. I think the other thing, and most importantly for me, which I thought was exciting just as someone who has commercialized eventually in the market, was the 53-minute onset. When you look at that compared to suzetrigine of 119 minutes, you saw 2.5x Faster onset of pain relief.
And then I think finally, as we think about what we talked about before with opioids and NSAIDs on both sides, good products for pain relief, but has a little bit of a messy profile when it comes to it. What we really have an opportunity to do with the NaV1.8 class is really come out with something that manages pain as effectively as these classes, but is very clean. And one of the other differences we saw is that we do not have drug-drug interactions with the initial data we are seeing, whereas I think we look at suzetrigine and the one thing they do have is some of the drug-drug interactions around the CYP3A.
For me, I got pretty excited when I think, number one, in the marketplace, I think every doctor will tell you, every patient will tell you, at the end of the day, how they determine the efficacy or whether a drug is working is really just onset.
Yeah.
The fact that we had that 53 minutes versus 119, 2.5x faster, is a differentiator that is significant. And then the SPID48 scores showed the overall clinical benefit. And then I think finally when you realize, at least right now, the data that is presenting seems to be continuing is that we do not have that drug-drug interaction. So reality is we could have a very, very clean product on market with significant efficacy. That becomes a game changer. But what we get the advantage of is launching second and saying, "Hey, we validated this class. We might have something that is, at least the data is saying, could be a better clinical option.
Okay. So you have one study in abdominoplasty, which is a phase III success. What is the regulatory requirement? Where are you going next? Why are you doing the bunionectomy study, and what would you like to show there?
Yeah. As people probably know, the guidance from the FDA is two placebo-controlled studies for approval. Bunionectomy would be the second placebo-controlled study that we have, again, looking at SPID48 as a primary endpoint. With that, we have about 480 patients. I think the news we shared last week in the Q3 update is that we're adding a Percocet arm to the bunionectomy study. One of the reasons we're doing that is, as we have confidence in the molecule, as we have confidence in the clinical performance, part of what we're starting to think about is strategically, how do you build out the package insert? How do you build out the label? Though the Percocet will not be a primary endpoint, we'll add an additional 80 patients for Percocet.
Just like in the Vicodin arm that we had in the abdominoplasty, placebo was the primary endpoint, Vicodin was secondary, and we looked at not only efficacy again, we looked at the side effect profile. That's very important because as we then transition to bunionectomy, which is, so you have soft tissue, now you have hard tissue, then you look at the idea that as placebo's a critical primary differentiator. What we want to build out, though, is this idea of opioid sparing, the ability to transition clinically from a belief that you have to use opioids that you can now replace with NaV1.8. The best way to do it is do what we did in abdominoplasty with Vicodin, where we showed significant efficacy differentiation.
We also saw about 52% opioid sparing, which was an important milestone when you think about how payers and policies are going to look at it. Again, to this direct question, as we look at bunionectomy, we're going to go with Percocet. The question came up, why do we add Percocet? Why didn't we do Vicodin? I think the important piece there is we have really, really good data against Vicodin, which is the most common written opioid for acute pain. Couple things when we were first putting together the bunionectomy study, I think a couple things. We hadn't had our IPO yet, so we didn't have a bunch of excess cash floating around, so you have to make some choices there. The approval was based on the placebo SPID48 differentiation.
Secondly then, once we saw the data that came out of the abdominoplasty, we wanted to be very careful because that's really good data. It's a very clean data set. We wanted to be careful not to just randomly add Vicodin again. Maybe we don't see the same results. Pain's notorious for that. Didn't want to kind of contaminate, so to speak, what we have. Once we had the IPO, obviously, we ended up with the cash we have now that gives us the flexibility to maybe take a little more risk, maybe take a little bit more aggressiveness as we look at expanding the commercial potential. At the same time, then the team, Neil, our CMO, came up with a really elegant solution, which said, "Why don't we use Percocet, right?" It's about 1.5x More potent than Vicodin.
It is also probably the second most commonly used product in acute pain. We put it and decided that that would be the right thing to do because it shows another comparison against opioid treatment. It would have an endpoint of potential non-inferiority against it, but more importantly, it is going to allow us to look at the AEs, the side effects, in that comparison. We entered it in there. We feel confident. First of all, the other big decision was not to change any of the timing. By adding the 80 patients, it allows us to maintain the second half 2027 readout, and it allows us to now have a broader base of opioids we are looking at, has another comparison. I think for us, the most important thing is then what that could mean for the label as we go forward.
Yeah. I think investors understand, and it was a right choice in my view to have that Percocet arm in the label, because again, it does not change the probability of success that anybody has on the study. I think the feedback we got from investor was that it does introduce some risk, right? There is a potential that you might either underperform or the delta might not be as robust as Vicodin. How would you address those questions? Obviously, you are confident you are going into it, but perhaps love to hear what gives you additional confidence? Just the profile of the drug?
Yeah. No, it is a great question because as we look at really approvability, the question is why would we add additional risk potentially with it? I think a couple things. First of all, I do not know that we necessarily We agree that obviously there is always risk when you add new variables. I think one of the things we did do is we looked at, went back and looked at a lot of data, and one of the things we did see is in bunionectomy studies, it did look like Vicodin and Percocet respond pretty similarly. So, it gave us some confidence that the results we saw against Vicodin, we have a chance to potentially see the same results in this trial against Percocet.
I think the second piece was that because Percocet is 1.5x more potent by the CDC guidelines than Vicodin, it opened the door for us that even if we were comparable or even slightly less, that that potency would not diminish the value of, A, the SPID scores that we are seeing and also the Vicodin data. We felt like the downside was very manageable, but we also felt like the upside, there was a lot of predictors that said we should be able to expect maybe similar behavior, Percocet to Vicodin in the arm.
Got it. In both the studies, you will have an opioid arm, right, as a competitor. How should we think about opioid-free claim? Is that something achievable? Is that important even from commercial standpoint? I know you're going to have all these data in the label, but just that particular claim.
Yeah. No, it's a great question because I think ultimately that is the goal we have, is how do you start replacing opioids clinically in the market once we're approved? The best way to do that is have more opioid data that shows opioid comparison. I think in the original data set that was published in The New England Journal of Medicine, the 52% opioid sparing is important data. What I think we're going to need to do, and I think what the FDA's kind of suggested is that we want opioid comparisons is what can lead us to that place, showing opioid sparing. I think for us, regardless if we get a clear or not clear opioid sparing, there's about three products on the market right now that recently, in the last 10 years, that got an opioid sparing.
We think we're putting the data set together that gives us the ability to negotiate for that.
Yeah.
More importantly for me at least, what I believe is important is as you build out the label, regardless of what the specific claim's going to be, because we'll have this opioid data. In the clinical trial section, you can build out and share this data both efficacy-wise and also side effects-wise, which opens the door for you to be able to promote for it, to be able to build it in the slide presentations, to be able to open the door for doctors to do their own studies and that sort of thing.
I think there's two pieces, right? Which is getting the opioid-free claim, which I think we're building out the data sets to do that with both Vicodin and Percocet. I think the second piece is, at the very least, it's going to give us a very powerful label that highlights us comparable to kind of a potency comparison, but more importantly, maybe a side effect in a clinical kind of experience.
Got it. What is the official guidance for data for bunionectomy?
For readout?
Yeah, for readout.
Second half of 2027.
Okay. Very good. Let's move to the chronic pain, LTG-321. Maybe talk about the product itself, what is that molecule, how it is differentiated, and what are you doing with the program?
Yeah. LTG-321 is differentiated from onzotrigine, from LTG-001. It's a different product in the sense that it is a once a day. It's showing once-a-day properties. We're studying it for OA, and the potency profile of it in OA is exciting for us. Obviously, as we know, OA is the largest of the pain markets out there. When you think there's about 250 million scripts out there, OA is probably the largest percentage of those scripts. OA is, for LTG-321, is going to be studied in the chronic indication for that, and that study is underway, and we're excited about that. That'll read out in second half of 2027 as well.
Got it. How do you look at the competitive dynamics here? Obviously, I think Lilly has a program which is early in development. Vertex is trying to expand. How do you stand? What are the advantages of being second to market?
Yeah. I think the good news is, as NaV1.8's been validated, we are seeing, as you mentioned, Lilly and some other companies. We're seeing some Chinese companies alsoâ
Yeah
âwith development there. AbbVie just recently licensed in that. We're excited about the investment, but we're clearly on pace to be second to market. I think second to market with a little bit of space between us. As a commercial person, being second to market with a differentiated product for meâ
Yeah
âyeah, it's pretty exciting. To Vertex's credit, they did a nice job launching the product, I think validating the target. I think they spent a lot of time and money bringing awareness. For me then, the idea is we have a differentiated product, as we talked about, right? Whether it's onsetâ
Yeah
âwhether it's DDIs. We get to now come to market, see what they did, bring a better solution or improved solution, and learn from everything that they've done well and maybe areas we can improve. That's going to be particularly important, not only on where you launch into, what targets, that sort of thing, but probably more importantly is how you engage the payers. As you guys probably saw with suzetrigine, they just last week announced their Q3, and they're settling into that 50%-60% gross-to-net. Gross-to-net's the number one commercial leverâ
Yeah
âthat exists in the space anymore as it gets to profitability and profitability per script. One of the things we think is our differentiation and engaging payers earlier is going to give us a way to navigate both getting clinical recognition for that differentiation, but then also understanding where it's important for the payers and how they manage that. Probably most importantly, for us, starting to prepare the market and looking at what's happening as we start to look at the policy evolutionâ
Yeah
âand understanding not only in the hospital where the NOPAIN Act is an important piece of helping reimbursement as you get novel products that can spare use of opioids. How does that expand, and then how do you expand that broader to maybe even outside of the hospital settings? For me, the competitive landscape, I think, is going to be a unique one because if we have the ability to launch in 18 months, two years, whatever that's going to be, there's going to be a lot of evolution, but there's also going to be a lot of demand, right? Vertex is already at two million scripts run rate . By the time we launch, my guess is they'll be well beyond that. That in itself is just phenomenal when you can walk into a doctor's office, say, "You like this NaV1.8 class.
Our efficacy, our side effects are better." What we can then do is besides doing that, we get the chance to start to expand the market where maybe people haven't been comfortable replacingâ
Yeah
âopioids yet or even NSAIDs yet. That's the exciting thing for me with a differentiated product is we get in this competitive side of it. I think as you look at things coming down the path, when you have our efficacy and when you have that clean profile, I'm not so sure I'm as worried aboutâ
Yeah
âthe next competitor that is going to come out if we have established ourselves and continue to innovate with LTG-321 and then LTG-418 beyond that.
Yeah. Maybe one more question, just again, broader question. How important it is to get a chronic indication approved? Because I think if you look at the class in general, and even with your program, I think acute is less risk because it is already successful in one study, you just have to replicate in the second study. So just curious to understand how important it is from a commercial standpoint, how big of that opportunity it is, and what about just acute itself?
Yeah. Yeah, so we have seen Vertex, obviously they got the acute pain indication.
Yeah.
But the product has not performed as well on the OA side of it.
Yeah.
They are pursuing more in the neuropathy side of things. For us, that is one of the things very important for us. We know that onzotrigine profile was the right profile for the acute space. LTG-321 is a differentiated molecule when we looked at some of the preclinical models. It is a predictor for it. There is validation for the OA space by some of the early Vertex work. As we look at that, we believe we have the right molecule to study. Getting out on the market to be able to offer a doctor an acute option and a chronic option as you get out into the orthopedic officeâ
Yeah
âand stuff like that is going to be very important. As I mentioned, the orthopedic or chronic pain is the largest market, mostly because you have refillsâ
Yeah
âbeyond those starts. Having that as part of it is really what makes Latigo a little bit different. Not only do we have really good fundamental molecules that are showing great results in the early trials, we also have a depth and a breadth of our platform and portfolio, with LTG-418 coming as a backup, as the next generation, early work being done in further assets, as well as maybe looking at multimodal type of places. I think having that come out validates that not only are we a one product potential, but that we have a portfolio to be that best in class, innovative pain company.
Got it. Final question then, how is the financial health? What is the cash runway? How does the balance sheet look like?
Yeah, no, we obviously had the IPO this summer, upsized about $100 million, so we're sitting on a balance sheet about $401 million, which we're seeing takes us into 2029. So we feel really good that all the work we have underway for the second half readouts is covered by what we have, and then carries us in 2029. We'll continue to then look at additional financing as we get the readout for the OA trial, or as the onzotrigine bunionectomy reads out, then eventually we'd be building out a bigger commercial into 2029. We'd look at further fundraising at that point.
Well, very good, Todd. Thank you so much. Congratulations on the new role, and 2027 is going to be a big year.
Well, thanks.